East Sunshine 2 diabetes compound preparation was first approved.

On August 18, Three new type 4 diabetes products (Liglitin metformin tablets, siglitin phosphate tablets and sigretin metformin tablets) were approved for listing by the State Drug Administration.
, Liglietine metformin tablets and sigretin metformin tablets for the domestic first imitation, phosphate siglitin tablets for the second domestic.
Sigretin and Liglietin, the former developed by Mercerton and the latter by Blinger Ingehan/Lilly.
2019, Merthyr Tydn's sales reached $3,482 million.
the domestic market, in addition to the original research products of MesaDong, is the first imitation of the day clear Sigretin has been approved.
Sigretin metformin tablets developed by Mercershadong were approved by the FDA in March 2007 and imported in China in July 2012 under the name Gynoda.
2019, Merthyr Tydn has sales of $2,041 million.
Ligliglitin metformin, originally developed by Blinger Ingehan/Lilly, was approved by the FDA in January 2012 and imported in China in March 2017 under the name Eusinin.
2019, Ossinin's global sales will be nearly $2.5 billion.
In the field of diabetes, Dongsai has previously been Gretin capsules, phosphate Liglietine tablets and recombinant human insulin injection 3 products approved for the market, this time also conducive to Gretin metformin tablets, phosphate sigretin tablets and sigridine diformin tablets were approved for the market, its diabetes product pipeline has been further enriched.
.